BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Telenti A, Iseman M. Drug-resistant tuberculosis: what do we do now? Drugs 2000;59:171-9. [PMID: 10730543 DOI: 10.2165/00003495-200059020-00002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Alghamdi S, Asif M. Study of Various Chemically and Structurally Diverse Currently Clinically Used and Recently Developed Antimycobacterial Drugs. Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex 2021. [DOI: 10.5772/intechopen.95538] [Reference Citation Analysis]
2 Pereira RS, Bauch CT, Penna TJP, Espíndola AL. A nested model for tuberculosis: Combining within-host and between-host processes in a single framework. Int J Mod Phys C 2021;32:2150167. [DOI: 10.1142/s0129183121501679] [Reference Citation Analysis]
3 Schultz M, Hernández JM, Hernández NE, Sanchez RO. Onset of tuberculosis disease: New converters in long-term care settings. Am J Alzheimers Dis Other Demen 2001;16:313-8. [DOI: 10.1177/153331750101600507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
4 Lotfian F, Mehrian P. Assessment of Cavitary Pulmonary Tuberculosis in Children. Arch Pediatr Infect Dis 2016;4. [DOI: 10.5812/pedinfect.35919] [Reference Citation Analysis]
5 Lotfian F, Bolursaz MR, Khalilzadeh S, Baghaie N, Hassanzad M, Velayati A. Features of Adolescents Tuberculosis at a Referral TB's Hospital in Tehran, Iran. Mediterr J Hematol Infect Dis 2016;8:e2016005. [PMID: 26740866 DOI: 10.4084/MJHID.2016.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 de Espíndola AL, Girardi D, Penna T, Bauch CT, Troca Cabella BC, Martinez AS. An antibiotic protocol to minimize emergence of drug-resistant tuberculosis. Physica A: Statistical Mechanics and its Applications 2014;400:80-92. [DOI: 10.1016/j.physa.2013.12.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Ibargüen-Mondragón E, Esteva L. On the interactions of sensitive and resistant Mycobacterium tuberculosis to antibiotics. Math Biosci 2013;246:84-93. [PMID: 23958384 DOI: 10.1016/j.mbs.2013.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
8 Asif M. Tuberculosis: Treatment-related Problems and Future Facets. Arch Clin Infect Dis 2013;8. [DOI: 10.5812/archcid.14413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Kumar K, Carrère-kremer S, Kremer L, Guérardel Y, Biot C, Kumar V. Azide–alkynecycloadditionen route towards 1H-1,2,3-triazole-tethered β-lactam–ferrocene and β-lactam–ferrocenylchalcone conjugates: synthesis and in vitro anti-tubercular evaluation. Dalton Trans 2013;42:1492-500. [DOI: 10.1039/c2dt32148c] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
10 Sonawane A, Mohanty S, Jagannathan L, Bekolay A, Banerjee S. Role of glycans and glycoproteins in disease development by Mycobacterium tuberculosis. Crit Rev Microbiol 2012;38:250-66. [PMID: 22324751 DOI: 10.3109/1040841X.2011.653550] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
11 Kumar K, Singh P, Kremer L, Guérardel Y, Biot C, Kumar V. Synthesis and in vitro anti-tubercular evaluation of 1,2,3-triazole tethered β-lactam–ferrocene and β-lactam–ferrocenylchalcone chimeric scaffolds. Dalton Trans 2012;41:5778. [DOI: 10.1039/c2dt30514c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
12 Asif M. Study of clinically used and recently developed antimycobacterial agents. Orient Pharm Exp Med 2012;12:15-34. [DOI: 10.1007/s13596-011-0020-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
13 Lu J, Qin R, Ye S, Yang M. Prunella vulgaris L. extract improves cellular immunity in MDR-TB challenged rats. Journal of Medical Colleges of PLA 2011;26:230-7. [DOI: 10.1016/s1000-1948(11)60040-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
14 Jenkin G. Isoniazid. Kucers' The Use of Antibiotics Sixth Edition 2010. [DOI: 10.1201/b13787-125] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Volokhov DV, Chizhikov VE, Denkin S, Zhang Y. Molecular detection of drug-resistant Mycobacterium tuberculosis with a scanning-frame oligonucleotide microarray. Methods Mol Biol 2009;465:395-417. [PMID: 20560062 DOI: 10.1007/978-1-59745-207-6_26] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
16 Hsueh C, Lin S, Lin C, Chien S, Liu W, Lin F, Tsai H, Huang C, Yang C. Quantitative diagnosis and analysis of mutations affecting drug resistance to rifampicin and isoniazid of clinical Mycobacterium tuberculosis isolates in Taiwan. Ann Microbiol 2010;60:391-397. [DOI: 10.1007/s13213-010-0054-z] [Reference Citation Analysis]
17 Jun L, Shan J, Song Y, Zongchang H. Sequence analysis on drug-resistant rpoB gene of Mycobacterium tuberculosis L-form of isolated from pneumoconiosis workers. Journal of Medical Colleges of PLA 2009;24:223-227. [DOI: 10.1016/s1000-1948(09)60041-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Changhong S, Hai Z, Limei W, Jiaze A, Li X, Tingfen Z, Zhikai X, Yong Z. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis 2009;89:54-61. [DOI: 10.1016/j.tube.2008.09.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
19 Hadda TB, Akkurt M, Baba MF, Daoudi M, Bennani B, Kerbal A, Chohan ZH. Anti-tubercular Activity of Ruthenium (II) Complexes with Polypyridines. Journal of Enzyme Inhibition and Medicinal Chemistry 2009;24:457-63. [DOI: 10.1080/14756360802188628] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
20 Ashokraj Y, Kaur KJ, Singh I, Kohli G, Bhade SR, Varma M, Agrawal S, Panchagnula R. In Vivo Dissolution: Predominant Factor Affecting the Bioavailability of Rifampicin in its Solid Oral Dosage Forms. Clinical Research and Regulatory Affairs 2008;25:1-12. [DOI: 10.1080/10601330701885041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Eoh H, Brennan PJ, Crick DC. The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target. Tuberculosis (Edinb) 2009;89:1-11. [PMID: 18793870 DOI: 10.1016/j.tube.2008.07.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
22 Bamuamba K, Gammon DW, Meyers P, Dijoux-franca M, Scott G. Anti-mycobacterial activity of five plant species used as traditional medicines in the Western Cape Province (South Africa). Journal of Ethnopharmacology 2008;117:385-90. [DOI: 10.1016/j.jep.2008.02.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
23 Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption -- a review on tuberculosis. Mem Inst Oswaldo Cruz 2006;101:697-714. [PMID: 17160276 DOI: 10.1590/s0074-02762006000700001] [Cited by in Crossref: 97] [Cited by in F6Publishing: 103] [Article Influence: 6.1] [Reference Citation Analysis]
24 Lu J, Jiang S, Ye S, Li C. Detecting Drug Resistant Genetic Mutation among pneumoconiosis patients complicated with tuberculosis in Mycobacterium tuberculosis L-forms Application of PCR-SSCP technique in Huainan mining district. Journal of Nanjing Medical University 2007;21:180-184. [DOI: 10.1016/s1007-4376(07)60042-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Eckert LO, Lentz GM. Infections of the Upper Genital Tract. Comprehensive Gynecology 2007. [DOI: 10.1016/b978-0-323-02951-3.50026-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Dixit PP, Patil VJ, Nair PS, Jain S, Sinha N, Arora SK. Synthesis of 1-[3-(4-benzotriazol-1/2-yl-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-3-substituted-thiourea derivatives as antituberculosis agents. European Journal of Medicinal Chemistry 2006;41:423-8. [DOI: 10.1016/j.ejmech.2005.12.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 3.4] [Reference Citation Analysis]
27 Sinha N, Jain S, Tilekar A, Upadhayaya RS, Kishore N, Jana GH, Arora SK. Synthesis of isonicotinic acid N'-arylidene-N-[2-oxo-2-(4-aryl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents. Bioorg Med Chem Lett 2005;15:1573-6. [PMID: 15745799 DOI: 10.1016/j.bmcl.2005.01.073] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
28 Tripathi RP, Tewari N, Dwivedi N, Tiwari VK. Fighting tuberculosis: An old disease with new challenges. Med Res Rev 2005;25:93-131. [DOI: 10.1002/med.20017] [Cited by in Crossref: 152] [Cited by in F6Publishing: 156] [Article Influence: 8.4] [Reference Citation Analysis]
29 Tewari N, Tiwari V, Tripathi R, Chaturvedi V, Srivastava A, Srivastava R, Shukla P, Chaturvedi A, Gaikwad A, Sinha S, Srivastava B. Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents. Bioorganic & Medicinal Chemistry Letters 2004;14:329-32. [DOI: 10.1016/j.bmcl.2003.11.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
30 &NA;. Therapeutic drug monitoring is a useful tool for a sub-set of patients with tuberculosis. Drugs & Therapy Perspectives 2003;19:13-16. [DOI: 10.2165/00042310-200319080-00005] [Reference Citation Analysis]
31 Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs. 2003;63:535-553. [PMID: 12656652 DOI: 10.2165/00003495-200363060-00002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
32 Morisky DE, Ebin VJ, Malotte CK, Coly A, Kominski G. Assessment of tuberculosis treatment completion in an ethnically diverse population using two data sources. Implications for treatment interventions. Eval Health Prof 2003;26:43-58. [PMID: 12629921 DOI: 10.1177/0163278702250080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
33 Rossetti MLR, Valim ARDM, Silva MSN, Rodrigues VS. Tuberculose resistente: revisão molecular. Rev Saúde Pública 2002;36:525-32. [DOI: 10.1590/s0034-89102002000400021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
34 Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M. Synthesis and antitubercular activity of imidazo[2,1-b]thiazoles. Eur J Med Chem 2001;36:743-6. [PMID: 11672884 DOI: 10.1016/s0223-5234(01)01266-1] [Cited by in Crossref: 108] [Cited by in F6Publishing: 111] [Article Influence: 5.1] [Reference Citation Analysis]
35 de Arriba Méndez J, Solera Santos J. Diagnóstico y tratamiento de la tuberculosis multirresistente. Revista Clínica Española 2002;202:335-338. [DOI: 10.1016/s0014-2565(02)71070-9] [Reference Citation Analysis]
36 Patnaik M, Liegmann K, Peter JB. Rapid detection of smear-negative Mycobacterium tuberculosis by PCR and sequencing for rifampin resistance with DNA extracted directly from slides. J Clin Microbiol 2001;39:51-2. [PMID: 11136747 DOI: 10.1128/JCM.39.1.51-52.2001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]